Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta‐analysis of randomized controlled trials
Pooled result · Cardiovascular deathResult — go to the resultOdds ratio 0.62 95% CI 0.39–0.99Authors' conclusion
Among adults with obesity or overweight, semaglutide and phentermine/topiramate were associated with greater body weight loss and waist circumference reduction at 12 months than all other drugs, and lower or no significant difference in risks of withdrawal. There was no evidence that drugs approved for weight management had different associations with cardiovascular death.
Study context
- Population
- Adults with obesity or overweight
- Participants
- 97,938 adults168 trials
- Comparison
- Drugs approved for weight management vs placebo and each other
- Outcome
- Cardiovascular death
Methodological detailsrandom-effects network meta-analysis, MEDLINE, Embase and CENTRAL searched through 26 February 2023
- Random-effects network meta-analysis
- MEDLINE, Embase and CENTRAL searched through 26 February 2023
Pooled result
As reported in the abstract
Odds ratio
0.62
95% CI 0.39–0.99
Naltrexone/bupropionvs Placebo
OR 0.62 (95% CI 0.39–0.99)
Further pooled results
| Outcome | MD (kg) (95% CI) | |
|---|---|---|
| Weight loss (33 trials, 37 616 participants); all drugs greater than placebo · 12 monthsSemaglutidevs PlaceboModerate certainty | −9.02 (−10.42 to −7.63) | |
| Weight loss (33 trials, 37 616 participants); all drugs greater than placebo · 12 monthsPhentermine/topiramatevs PlaceboHigh certainty | −8.10 (−10.14 to −6.05) | |
| −15−10−505Difference, kg (linear scale) |
| Outcome | MD (cm) (95% CI) | |
|---|---|---|
| Waist circumference reduction (24 trials, 35 733 participants); all drugs greater than placebo · 12 monthsSemaglutidevs PlaceboModerate certainty | −7.84 (−9.34 to −6.34) | |
| Waist circumference reduction (24 trials, 35 733 participants); all drugs greater than placebo · 12 monthsPhentermine/topiramatevs PlaceboHigh certainty | −6.20 (−7.46 to −4.94) | |
| −10−505Difference, cm (linear scale) |
Safety
Treatment withdrawal (87 trials, 70 860 participants)
- Semaglutide and phentermine/topiramate associated with lower or no difference in odds of treatment withdrawal vs all other drugs
Original publication
Clinical outcomes associated with drugs for obesity and overweight: A systematic review and network meta‐analysis of randomized controlled trials. Diabetes Obes Metab. Published 31 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →